Simcere Pharmaceutical Group Ltd. announced a further revision of the 2025 and 2026 annual caps under its Exclusive Promotion Services Cooperation Agreement with Beijing Simcere Sanroad. The agreement, effective from January 16, 2024, grants Beijing Simcere Sanroad exclusive promotion rights for the Group's generic drug, Fumarate Bedaquiline Tablets, within specified indications and regions. The cooperation agreement remains valid until December 31, 2026. The company stated that aside from the revised annual caps, all other terms and conditions of the agreement remain unchanged.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.